Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy
Citations Over TimeTop 10% of 2012 papers
Abstract
Clinical observations reveal that an augmented pace of T-cell recovery after chemotherapy correlates with improved tumor-free survival, suggesting the add-back of T cells after chemotherapy may improve outcomes. To evaluate adoptive immunotherapy treatment for B-lineage non-Hodgkin lymphoma (NHL), we expanded T cells from client-owned canines diagnosed with NHL on artificial antigen presenting cells (aAPC) in the presence of human interleukin (IL)-2 and IL-21. Graded doses of autologous T cells were infused after CHOP chemotherapy and persisted for 49 days, homed to tumor, and significantly improved survival. Serum thymidine kinase changes predicted T-cell engraftment, while anti-tumor effects correlated with neutrophil-to-lymphocyte ratios and granzyme B expression in manufactured T cells. Therefore, chemotherapy can be used to modulate infused T-cell responses to enhance anti-tumor effects. The companion canine model has translational implications for human immunotherapy which can be readily exploited since clinical-grade canine and human T cells are propagated using identical approaches.
Related Papers
- → Evaluation of a 15‐weekCHOPprotocol for the treatment of canine multicentric lymphoma(2012)81 cited
- → RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy(2022)6 cited
- → RNA disruption indicates CHOP therapy efficacy in canine lymphoma(2019)12 cited
- → Calculation of dose intensity and comparison of published methods using a cohort of canine T‐cell lymphoma patients undergoing CHOP‐based chemotherapy(2023)3 cited
- → Dose Intensive CHOP Protocol for Canine Multicentric Lymphoma(2014)